Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) has filed a new patent application (N2039646) for allergic inflammation therapy, developed through AI drug repurposing in collaboration with Cloudpharm and the National Hellenic Research Foundation. The patent leverages their AI-powered Cloudscreen platform and experimental data to repurpose an existing marketed drug, targeting key inflammatory pathways through a novel mechanism.
The initiative addresses a significant market opportunity, as allergic conditions affect 10-30% of the global population according to BMJ Open 2024. The global allergy treatment market, valued at $23.5 billion in 2024, is projected to reach $37.0 billion by 2033, growing at a CAGR of 4.92%.
Positive
- Patent application filed for novel allergic inflammation therapy using AI drug repurposing
- Targeting large market opportunity with 10-30% of global population affected by allergies
- Addressing growing market valued at $23.5B with projected growth to $37.0B by 2033
Negative
- None.
Insights
This patent application marks a significant strategic pivot for Cosmos Health, leveraging AI-driven drug repurposing to target the
Three key factors make this development particularly noteworthy:
- The collaboration with established institutions (Cloudpharm and National Hellenic Research Foundation) adds scientific credibility and reduces development risk
- The focus on a marketed drug with a novel mechanism of action could accelerate the regulatory pathway, as safety profiles are already established
- The targeted market shows robust growth potential, with a projected CAGR of
4.92% through 2033
However, investors should note that COSM faces significant challenges in this space. The company will need to navigate complex patent landscapes, demonstrate clinical efficacy and compete with established pharmaceutical companies that dominate the allergy treatment market. The success of this initiative will largely depend on the strength of the patent claims and the company's ability to protect its intellectual property.
The strategic value extends beyond the immediate patent application. This development represents COSM's evolution from a primarily distribution-focused business to one with potential high-margin proprietary treatments. The AI-driven approach could also be leveraged for future drug development programs, potentially creating a scalable platform for additional therapeutic areas.
The implementation of AI-driven drug repurposing through the Cloudscreen platform represents a cutting-edge approach that could significantly reduce both the time and cost of bringing new treatments to market. This technology typically increases drug development success rates by 25-30% compared to traditional methods, primarily by identifying previously unknown relationships between existing compounds and therapeutic targets.
Key technological advantages include:
- Rapid screening of thousands of approved compounds against new therapeutic targets
- Identification of novel mechanisms of action that might be overlooked by conventional research methods
- Reduced risk of failure in clinical trials due to existing safety data for approved drugs
The collaboration with established research institutions suggests a robust validation process for the AI-generated insights. This hybrid approach, combining computational predictions with experimental validation, significantly increases the likelihood of successful drug repurposing while maintaining scientific rigor.
The technology platform could become a valuable asset beyond this specific application, potentially generating additional opportunities in other therapeutic areas and creating a sustainable competitive advantage in drug discovery.
CHICAGO, IL / ACCESS Newswire / January 27, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a new patent application for allergic inflammation, a condition characterized by immune system hypersensitivity.
The application, filed under Application Number N2039646 in collaboration with Cloudpharm and the National Hellenic Research Foundation, with the support of the pharma patent expert team at NLO, represents a significant step in the Company's efforts to develop cutting-edge therapeutic options for inflammatory conditions.
The patent is supported by predictive insights from Cosmos Health's AI-powered Cloudscreen drug repurposing platform, combined with recent experimental data. These findings highlight the potential of a repurposed marketed drug to modulate key inflammatory pathways through a novel mechanism of action identified by the inventors.
These advancements reaffirm Cosmos Health's commitment to tackling severe allergic conditions and delivering innovative treatments to improve patient care and quality of life.
Allergic Inflammation
Allergic diseases are characterized by an immune system overreaction to typically harmless substances, such as pollen, dust, or certain foods. Over recent decades, the prevalence of allergic conditions has risen significantly, with BMJ Open 2024 reporting that they now affect approximately 10
Global Market Overview
According to Imarc Group, the global allergy treatment market has been experiencing substantial growth, driven by the increasing prevalence of allergic conditions and advancements in therapeutic options. In 2024, the market was valued at approximately
Greg Siokas, CEO of Cosmos Health, stated: "This patent application is a critical addition to our intellectual property portfolio, reinforcing our dedication to addressing the growing challenges of allergic conditions. By leveraging our AI-driven drug repurposing platform, we continue to push the boundaries of innovation to develop impactful solutions that improve patient care worldwide."
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
What is the market size for allergy treatments targeted by Cosmos Health (COSM)?
What is the patent application number for COSM's new allergic inflammation therapy?
Who are COSM's partners in developing the new allergy treatment patent?
What percentage of the global population is affected by allergic conditions according to COSM's research?
What technology did COSM use to develop its new allergy treatment?
